See more : Tele2 AB (publ) (TEL2-A.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Tekla Life Sciences Investors (HQL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tekla Life Sciences Investors, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Crown Resorts Limited (CWLDY) Income Statement Analysis – Financial Results
- Aesthetic Medical International Holdings Group Limited (AIH) Income Statement Analysis – Financial Results
- NGL Energy Partners LP (NGL-PB) Income Statement Analysis – Financial Results
- Vixtel Technologies Holdings Limited (1782.HK) Income Statement Analysis – Financial Results
- OAT Agrio Co., Ltd. (4979.T) Income Statement Analysis – Financial Results
Tekla Life Sciences Investors (HQL)
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.69M | 23.52M | -103.25M | 65.69M | 124.08M | -69.34M | 29.82M | 69.81M | 6.29M | 1.32M | 876.79K | 516.76K | 2.14M | 570.00K | 1.82M | 460.00K | 1.67M | 2.88M | 2.30M | 890.00K | 320.00K | 610.00K | 940.00K | 1.77M | 140.00K | 320.00K | 420.00K |
| Cost of Revenue | 0.00 | 5.24M | 5.55M | 6.08M | 5.21M | 5.00M | 4.77M | 4.61M | 4.95M | 5.65M | 4.14M | 3.10M | 2.48M | 3.02M | 2.99M | 2.85M | 3.76M | 3.62M | 2.93M | 2.81M | 2.78M | 2.44M | 2.86M | 3.26M | 1.64M | 1.63M | 1.60M |
| Gross Profit | 86.69M | 18.28M | -108.80M | 59.61M | 118.88M | -74.35M | 25.05M | 65.20M | 1.34M | -4.33M | -3.26M | -2.58M | -335.50K | -2.45M | -1.17M | -2.39M | -2.09M | -740.00K | -630.00K | -1.92M | -2.46M | -1.83M | -1.92M | -1.49M | -1.50M | -1.31M | -1.18M |
| Gross Profit Ratio | 100.00% | 77.71% | 105.37% | 90.75% | 95.80% | 107.22% | 84.00% | 93.40% | 21.34% | -327.02% | -372.18% | -499.89% | -15.64% | -429.82% | -64.29% | -519.57% | -125.15% | -25.69% | -27.39% | -215.73% | -768.75% | -300.00% | -204.26% | -84.18% | -1,071.43% | -409.38% | -280.95% |
| Research & Development | 0.00 | 0.00 | -3.28 | 1.43 | 3.15 | -1.84 | 0.80 | 1.46 | -1.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | 5.23M | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.33M | 903.14K | 1.08M | 844.02K | 751.32K | 876.76K | 880.76K | 991.51K | -1.89 | 6.04M | 4.64M | 3.69M | 3.43M | 1.15M | 630.00K | 590.00K | 680.00K | 720.00K | 550.00K | 510.00K | 530.00K | 450.00K | 470.00K | 340.00K | 230.00K | 190.00K | 0.00 |
| Other Expenses | 85.35M | 22.62M | 275.97K | 313.69K | 278.66K | 259.76K | 466.64K | 423.33K | 20.74M | 143.44K | 130.00K | 150.00K | 200.00K | 200.00K | 160.00K | 170.00K | 140.00K | 250.00K | 160.00K | 150.00K | 80.00K | 60.00K | 120.00K | 110.00K | 10.00K | 40.00K | 290.00K |
| Operating Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 1.16M | 1.26M | 13.35M | 39.18M | 88.39M | 84.13M | 75.49M | 1.35M | 790.00K | 760.00K | 820.00K | 970.00K | 710.00K | 660.00K | 610.00K | 510.00K | 590.00K | 450.00K | 240.00K | 230.00K | 290.00K |
| Cost & Expenses | 86.69M | 23.52M | 1.35M | 1.16M | 1.03M | 1.14M | 5.59M | 5.56M | 1.34M | 39.18M | 88.39M | 84.13M | 75.49M | 4.37M | 3.78M | 3.61M | 4.58M | 4.59M | 3.64M | 3.47M | 3.39M | 2.95M | 3.45M | 3.71M | 1.88M | 1.86M | 1.89M |
| Interest Income | 1.04M | 204.45K | 50.09K | 0.00 | 164.80K | 216.70K | 90.71K | 90.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27M | 72.43M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 0.00 | 27.60M | 2.99M | 4.14M | 2.11M | 2.88M | 3.61M | 3.88M | 3.79M | 4.72M | 3.77M | 3.17M | 1.28M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| EBITDA | 0.00 | 22.35M | -104.61M | 64.54M | 123.06M | -70.47M | 28.67M | 68.56M | 0.00 | 0.00 | 0.00 | 0.00 | 78.91M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| EBITDA Ratio | 0.00% | 95.03% | 101.31% | 98.24% | 99.17% | 101.64% | 204.33% | 201.96% | 289.30% | 3,419.13% | 10,610.66% | 16,993.50% | 3,679.80% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Operating Income | 0.00 | -5.24M | -104.60M | 64.53M | 123.05M | -70.48M | -3.61M | -3.88M | -3.79M | -4.72M | -3.77M | -3.17M | -1.28M | -3.80M | -1.96M | -3.15M | -2.92M | -1.71M | -1.34M | -2.59M | -3.07M | -2.34M | -2.52M | -1.94M | -1.75M | -1.53M | -1.47M |
| Operating Income Ratio | 0.00% | -22.29% | 101.31% | 98.24% | 99.17% | 101.64% | -12.10% | -5.56% | -60.25% | -357.04% | -429.50% | -613.43% | -59.85% | -666.67% | -107.69% | -684.78% | -174.85% | -59.38% | -58.26% | -291.01% | -959.38% | -383.61% | -268.09% | -109.60% | -1,250.00% | -478.13% | -350.00% |
| Total Other Income/Expenses | 85.30M | 27.60M | -101.61M | 6.08M | 5.21M | -67.60M | 32.61M | 72.74M | -8.12M | 45.22M | 93.03M | 87.82M | 78.91M | 41.27M | 12.15M | -18.52M | 63.17M | 52.22M | -20.10M | 47.35M | 10.23M | 40.96M | -47.89M | -93.09M | -28.63M | 16.72M | 23.28M |
| Income Before Tax | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Income Before Tax Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.33% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| Income Tax Expense | 0.00 | 0.00 | -2.99M | -4.15M | -2.13M | -2.88M | 1.00 | 3.00 | 26.32M | 45.22M | 93.03M | 87.82M | 78.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 85.30M | 22.35M | -104.60M | 64.53M | 123.05M | -70.48M | 28.66M | 68.56M | -11.91M | 40.50M | 89.27M | 84.65M | 77.63M | 37.47M | 10.19M | -21.67M | 60.25M | 50.51M | -21.44M | 44.76M | 7.16M | 38.62M | -50.41M | -95.03M | -30.38M | 15.19M | 21.81M |
| Net Income Ratio | 98.40% | 95.02% | 101.31% | 98.24% | 99.17% | 101.64% | 96.12% | 98.20% | -189.30% | 3,062.09% | 10,181.17% | 16,380.07% | 3,619.95% | 6,573.68% | 559.89% | -4,710.87% | 3,607.78% | 1,753.82% | -932.17% | 5,029.21% | 2,237.50% | 6,331.15% | -5,362.77% | -5,368.93% | -21,700.00% | 4,746.88% | 5,192.86% |
| EPS | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.28 | 3.21 | 1.00 | 2.06 | 4.70 | 5.65 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| EPS Diluted | 0.00 | 0.79 | -4.07 | 2.66 | 5.16 | -3.04 | 1.23 | 3.21 | 20.74M | 2.06 | 4.70 | 5.64 | 5.38 | 2.57 | 0.47 | -0.99 | 2.86 | 2.52 | -1.11 | 3.55 | 0.59 | 3.38 | -4.84 | -10.20 | -4.17 | 2.17 | 3.26 |
| Weighted Avg Shares Out | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 22.41M | 21.36M | -11.91M | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
| Weighted Avg Shares Out (Dil) | 28.06M | 28.29M | 25.68M | 24.26M | 23.85M | 23.18M | 23.30M | 21.36M | -0.57 | 19.69M | 19.01M | 14.99M | 14.43M | 14.58M | 21.84M | 21.95M | 21.08M | 20.08M | 19.23M | 12.61M | 12.07M | 11.41M | 10.41M | 9.32M | 7.29M | 7.01M | 6.68M |
Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.
HQL: A Biotechnology Equity CEF With No Leverage
Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while its 10-year range annualized return sits at 9.8%.
HQL: Buy For The Yield, If You Can Stomach The Depreciation
HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is impressive. In the past three months, a dividend cut and extension of buyback period played...
How To Protect Your Wealth, Grab 7%+ Dividends, In This Pullback
You can be forgiven if your stomach tightens just a bit when you go to check your retirement account.
Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive.
5 Closed-End Funds Bought In November
5 Closed-End Funds Bought In November
Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Tekla Life Sciences Investors Declares Distribution
BOSTON--(BUSINESS WIRE)--On August 17, 2021, Tekla Life Sciences Investors declared a distribution of $0.43 per share. The record date for the stock distribution is August 27, 2021 and the payable date is September 30, 2021. The Fund will trade ex-distribution...
5 Dividend Funds Yielding Up To 27.2%
Double-digit dividends are rare. A sky-high yield of 27.2% is an outright income unicorn.
Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector
As an income investor, the 7.8% yield is quite attractive to me if HQL can support it. I continue my series on CEFs looking beyond the yield.
Source: https://incomestatements.info
Category: Stock Reports